Key Features

  • Sample Size: 240 Pharmacists from BC, AB, SK, ON, QC, NB, NL and NS.
  • Final Deliverable: PowerPoint presentation with executive summary of key findings.
  • Field Timing: December 2014.
  • Report Delivery: February 2015.
 

Over the past few years a number of Canadian provinces have amended or revised their legislation furthering the scope of practice for health professionals in order to accommodate the growing demands for patient care on the healthcare system. The expanded scope of practice specific to Pharmacists has the potential to significantly impact prescribing and ultimately the ways in which pharmaceutical manufacturers communicate and market their products.

Whereas traditional pharmaceutical marketing in Canada has primarily targeted the physician as being the only ‘authorized prescriber’, recent changes to national and provincial legislation has altered the playing field with the resultant emergence of a new authorized prescribing group.

This report on pharmacist prescribing provides an in-depth province-by-province review of the expanded practice scope of Pharmacists. Building on the key findings from this expanded report, first published in 2009; it will also include tracking on key awareness and usage trends to further analyze potential impact and rate of uptake.

With this study you will acquire a detailed understanding of the evolving prescribing authorization amongst Pharmacists. Gain a better understanding where the opportunities are to initiate new prescriptions. As well as, learn how to develop finely tuned communication strategies by province and therapeutic categories to grow and protect your scripts through changes in dosing, adaptation or substitution of a physician provided prescription.

Key Objectives

  • Determine the current prescribing latitude of Pharmacists by province.
  • Assess Pharmacists’ awareness levels for their increased authority and role in the prescribing of medication.
  • Determine the degree to which prescribing by Pharmacists are taking place.
  • Examine the current and future impact of theses new prescribing groups on drug selection, change, review and substitution.